Abstract
Gene amplification is common in solid tumors and is associated with adverse prognosis, disease progression, and development of drug resistance. A small segment from chromosome 17q11–12 containing the HER-2/Neu gene is amplified in about 25% of breast cancer. HER-2/Neu amplification is associated with adverse prognosis and may predict response to chemotherapy and hormonal manipulation. Moreover, HER-2/Neu amplification may select patients for anti-HER-2/Neu-based therapy with Herceptin. We and others recently described a common sequence element from the HER-2/Neu region that was amplified in breast cancer cells. In addition, most, if not all, of the amplified genes from this region display overexpression. This raises the intriguing possibility that genes immediately adjacent to HER-2/Neu may influence the biological behavior of breast cancer carrying HER-2/Neu amplification and serve as rational targets for therapy. By extracting sequence information from public databases, we have constructed a contig in bacterial artificial chromosomes (BACs) that extends from HER-2/Neu to a phosphotidylinositol phosphate kinase (PIPK), Pip4k2β from 17q11–12. Although a role of PI-3-kinase and AKT in cancer biology has been previously described, PIPK has not been previously implicated. We show that Pip4k2β, initially known as Pip5k2β, is amplified in a subset of breast cancer cell lines and primary breast cancer samples that carry HER-2/Neu amplification. Out of eight breast cancer cell lines with HER-2/Neu amplification, three have concomitant amplification of the Pip4k2β gene – UACC-812, BT-474 and ZR-75-30. Similarly, two out of four primary breast tumors with HER-2/Neu amplification carry Pip4k2β gene amplification. Intriguingly, one tumor displays an increase in the gene copy number of Pip4k2β that is significantly more than that of HER-2/Neu. Moreover, dual color FISH reveals that amplified Pip4k2β gene may exist in a distinct structure from that of HER-2/Neu in ZR-75-30 cell line. These studies suggest that Pip4k2β may reside on an amplification maximum distinct from that of HER-2/Neu and serve as an independent target for amplification and selective retention. Pip4k2β amplification is associated with overexpression at the RNA and protein level in breast cancer cell lines. Stable expression of Pip4k2β in breast cancer cell lines with and without HER-2/Neu amplification increases cell proliferation and anchorage-independent growth. The above observations implicate Pip4k2β in the development and/or progression of breast cancer. Our study suggests that Pip4k2β may be a distinct target for gene amplification and selective retention from 17q11–12.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Amler LC and Schwab M . (1989). Mol. Cell. Biol., 9, 4903–4913.
Anderson RA, Boronenkov IV, Doughman SD, Kunz J and Loijens JC . (1999). J. Biol. Chem., 274, 9907–9910.
Arneson LS, Kunz J, Anderson RA and Traub LM . (1999). J. Biol. Chem., 274, 17794–17805.
Barlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi O-P and Kallioniemi A . (2000). Cancer Res., 60, 5340–5344.
Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Panici PB, Mancuso S, Neri G and Testa JR . (1995). Int. J. Cancer, 64, 280–285.
Brien TP, Odze RD, Sheehan CE, McKenna BJ and Ross JS . (2000). Hum. Pathol., 31, 35–39.
Bringuier PP, Tamimi Y, Schuuring E and Schalken J . (1996). Oncogene, 12, 1747–1753.
Castellino AM, Parker GJ, Boronenkov IV, Anderson RA and Chao MV . (1997). J. Biol. Chem., 272, 5861–5870.
Chazin VR, Kaleko M, Miller AD and Slamon DJ . (1992). Oncogene, 7, 1859–1866.
Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR . (1992). Proc. Natl. Acad. Sci. USA, 89, 9267–9271.
Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK and Testa JR . (1996). Proc. Natl. Acad. Sci. USA, 93, 3636–3641.
Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR and Aaronson SA . (1987). Science, 237, 178–182.
Fruman DA, Meyers RE and Cantley LC . (1998). Annu. Rev. Biochem., 67, 481–507.
Gary JD, Wurmser AE, Bonangelino CJ, Weisman LS and Emr SD . (1998). J. Cell. Biol., 143, 65–79.
Gaudray P, Szepetowski P, Escot C, Birnbaum D and Theillet C . (1992). Mutat. Res., 276, 317–328.
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD and Muller WJ . (1992). Proc. Natl. Acad. Sci. USA, 89, 10578–10582.
Hay JC, Fisette PL, Jenkins GH, Fukami K, Takenawa T, Anderson RA and Martin TF . (1995). Nature, 374, 173–177.
Homma K, Terui S, Minemura M, Qadota H, Anraku Y, Kanaho Y and Ohya Y . (1998). J. Biol. Chem., 273, 15779–15786.
Huang CL, Feng S and Hilgemann DW . (1998). Nature, 391, 803–806.
Hudziak RM, Schlessinger J and Ullrich A . (1987). Proc. Natl. Acad. Sci. USA, 84, 7159–7163.
Ishihara H, Shibasaki Y, Kizuki N, Wada T, Yazaki Y, Asano T and Oka Y . (1998). J. Biol. Chem., 273, 8741–8748.
Ishikawa T, Kobayashi M, Mai M, Suzuki T and Ooi A . (1997). Am. J. Pathol., 151, 761–768.
Kauraniemi P, Barlund M, Monni O and Kallioniemi A . (2001). Cancer Res., 61, 8235–8240.
Kunz J, Wilson MP, Kisseleva M, Hurley JH, Majerus PW and Anderson RA . (2000). Mol. Cell, 5, 1–11.
Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A and Peters G . (1991). Oncogene, 6, 439–444.
Lammie GA and Peters G . (1991). Cancer Cells, 3, 413–420.
Luoh SW . (2002). Cancer Genet. Cytogenet., 136, 43–47.
Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM and Gray JW . (2002). Cancer Res., 62, 3636–3640.
McEwen RK, Dove SK, Cooke FT, Painter GF, Holmes AB, Shisheva A, Ohya Y, Parker PJ and Michell RH . (1999). J. Biol. Chem., 274, 33905–33912.
Mejillano M, Yamamoto M, Rozelle AL, Sun HQ, Wang X and Yin HL . (2001). J. Biol. Chem., 276, 1865–1872.
Monni O, Barlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, Paavola P, Avela K, Chen Y, Bittner ML and Kallioniemi A . (2001). Proc. Natl. Acad. Sci. USA, 98, 5711–5716.
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M and Henderson IC . (1994). N. Engl. J. Med., 330, 1260–1266.
Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T and Nakano H . (1999). Cancer, 85, 1894–1902.
Nessling M, Solinas-Toldo S, Wilgenbus KK, Borchard F and Lichter P . (1998). Genes Chromosomes Cancer, 23, 307–316.
Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL and Wolmark N . (1998). J. Natl. Cancer Inst., 90, 1361–1370.
Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R and Slamon DJ . (2000). J. Clin. Oncol., 18, 3651–3664.
Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX and Slamon DJ . (1995). Oncogene, 10, 2435–2446.
Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M and Akita R . (1993). Cancer Res., 53, 4960–4970.
Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ and Batsakis JG . (1994). Cancer Res., 54, 5675–5682.
Proctor AJ, Coombs LM, Cairns JP and Knowles MA . (1991). Oncogene, 6, 789–795.
Rameh LE, Tolias KF, Duckworth BC and Cantley LC . (1997). Nature, 390, 192–196.
Rao VD, Misra S, Boronenkov IV, Anderson RA and Hurley JH . (1998). Cell, 94, 829–839.
Ravdin PM and Chamness GC . (1995). Gene, 159, 19–27.
Roelofs H, Schuuring E, Wiegant J, Michalides R and Giphart-Gassler M . (1993). Genes Chromosomes Cancer, 7, 74–84.
Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ and Niemann TH . (1999). Int. J. Gynecol. Pathol., 18, 138–143.
Ross JS and Fletcher JA . (1999). Semin. Cancer Biol., 9, 125–138.
Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA and Muraca PJ . (1997). Hum. Pathol., 28, 827–833.
Rozenvayn N and Flaumenhaft R . (2001). J. Biol. Chem., 276, 22410–22419.
Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Benard J, Delattre O, Favrot M, Peyroulet MC, Thyss A, Perel Y, Bergeron C, Courbon-Collet B, Vannier JP, Lemerle J and Sommelet D . (1997). J. Clin. Oncol., 15, 1171–1182.
Savelyeva L and Schwab M . (2001). Cancer Lett., 167, 115–123.
Sbrissa D, Ikonomov OC and Shisheva A . (1999). J. Biol. Chem., 274, 21589–21597.
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY and Hammond D . (1985). N. Engl. J. Med., 313, 1111–1116.
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V and Kitchen P . (1993). J. Clin. Oncol., 11, 1936–1942.
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW . (1999). Nat. Genet., 21, 99–102.
Shibasaki Y, Ishihara H, Kizuki N, Asano T, Oka Y and Yazaki Y . (1997). J. Biol. Chem., 272, 7578–7581.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL . (1987). Science, 235, 177–182.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF . (1989). Science, 244, 707–712.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L . (2001). N. Engl. J. Med., 344, 783–792.
Szepetowski P, Courseaux A, Carle GF, Theillet C and Gaudray P . (1992). Oncogene, 7, 751–755.
Szepetowski P, Perucca-Lostanlen D and Gaudray P . (1993). Genomics, 16, 745–750.
Theillet C, Adnane J, Szepetowski P, Simon MP, Jeanteur P, Birnbaum D and Gaudray P . (1990). Oncogene, 5, 147–149.
Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L and Liu ET . (1998). J. Natl. Cancer Inst., 90, 1346–1360.
Tolias KF, Rameh LE, Ishihara H, Shibasaki Y, Chen J, Prestwich GD, Cantley LC and Carpenter CL . (1998). J. Biol. Chem., 273, 18040–18046.
Walch AK, Zitzelsberger HF, Bink K, Hutzler P, Bruch J, Braselmann H, Aubele MM, Mueller J, Stein H, Siewert JR, Hofler H and Werner M . (2000). Mod. Pathol., 13, 814–824.
Wu G, Sinclair C, Hinson S, Ingle JN, Roche PC and Couch FJ . (2001). Cancer Res., 61, 4951–4955.
Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD and Couch FJ . (2000). Cancer Res., 60, 5371–5375.
Zhang X, Loijens JC, Boronenkov IV, Parker GJ, Norris FA, Chen J, Thum O, Prestwich GD, Majerus PW and Anderson RA . (1997). J. Biol. Chem., 272, 17756–17761.
Acknowledgements
I (S-WL) thank Drs Dennis J Slamon and Owen N Witte for mentorship and support. We thank Drs Bob Franco, Tom Clemans, Jeff Kanuf, and Peter Stambrook for careful review of the manuscripts. S-WL was a recepient of Fellow Scholarship from American Society of Hematology. This paper is dedicated to the loving memory of late Dr Ching-Shuenn Luoh.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Luoh, SW., Venkatesan, N. & Tripathi, R. Overexpression of the amplified Pip4k2β gene from 17q11–12 in breast cancer cells confers proliferation advantage. Oncogene 23, 1354–1363 (2004). https://doi.org/10.1038/sj.onc.1207251
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207251
Keywords
This article is cited by
-
Beyond PI3Ks: targeting phosphoinositide kinases in disease
Nature Reviews Drug Discovery (2023)
-
Circulating non-coding RNAs as a diagnostic and management biomarker for breast cancer: current insights
Molecular Biology Reports (2022)
-
Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
Scientific Reports (2019)
-
Genetical genomics of growth in a chicken model
BMC Genomics (2018)
-
PIPKIIα is widely expressed in hematopoietic-derived cells and may play a role in the expression of alpha- and gamma-globins in K562 cells
Molecular and Cellular Biochemistry (2014)